Schnitzler syndrome: Treatment failure to rituximab but response to anakinra - 19/08/11
Kiel, Germany
Abstract |
Schnitzler syndrome is a rare disease characterized by a chronic urticarial rash and a monoclonal gammopathy. The exact pathogenesis is still uncertain and treatment remains a challenge. Here, we report a patient who was only recently given the diagnosis of Schnitzler syndrome although the typical symptoms had been present for about 6 years. Administration of the B-cell antibody rituximab did not exert any beneficial effect despite effective elimination of B cells and a reduction of the paraprotein. In contrast, injection of the interleukin-1-receptor antagonist anakinra caused a complete remission within a few days.
Le texte complet de cet article est disponible en PDF.Plan
Funding sources: None. Conflicts of interest: None declared. |
Vol 57 - N° 2
P. 361-364 - août 2007 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?